Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
Launched by DANIELLE KIM TURGEON · Mar 10, 2020
Trial Information
Current as of June 27, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Subject meets all of the following criteria:
- • Scheduled for an outpatient ERCP to diagnose a potential biliary disorder (such as an indeterminate biliary stricture)
- • Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities)
- • Age 18 to 100 years
- • Willing and able to sign informed consent
- Exclusion Criteria:
- • Subjects with known allergy or negative reaction to any components of the study drug (list these)
- • Subjects on active chemotherapy or radiation treatment
- • Pregnant or trying to conceive
- • Anything that, in the opinion of the investigator, would place the individual at increased risk or preclude the individual's full compliance with or completion of the study
About Danielle Kim Turgeon
Danielle Kim Turgeon is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovative therapies. With a focus on patient safety and regulatory compliance, she leads the design and execution of clinical trials that aim to evaluate the efficacy and safety of new treatments across various therapeutic areas. Leveraging her extensive expertise in clinical development and a collaborative approach, Danielle fosters partnerships with research institutions and healthcare professionals to ensure rigorous study protocols and optimal patient recruitment. Her leadership is marked by a passion for improving healthcare outcomes and a deep understanding of the complexities of the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Danielle Kim Turgeon, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials